Vyome Holdings (HIND) Liabilities and Shareholders Equity (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Liabilities and Shareholders Equity of $10.2 million for Q1 2026, up 605.81% year-over-year from $1.4 million in Q1 2025, and up 56.77% quarter-over-quarter from $6.5 million in Q4 2025.
Vyome Holdings (HIND) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
Vyome Holdings' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $10.2 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 605.81% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $32.8 million (up 212.08% YoY), while the FY2025 annual figure was $6.5 million, up 370.28% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $10.2 million, up from $6.5 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $45.6 million in Q1 2022, with the low at $1.3 million in Q3 2024.
- The 5-year median for Liabilities and Shareholders Equity is $9.0 million (2025), against an average of $13.0 million.
- The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity sank 87.04% in 2024, then soared 605.81% in 2026.
- Vyome Holdings' Liabilities and Shareholders Equity stood at $11.1 million in 2022, then retreated by 4.3% to $10.7 million in 2023, then tumbled by 87.04% to $1.4 million in 2024, then jumped by 370.28% to $6.5 million in 2025, then jumped by 56.77% to $10.2 million in 2026.
- Business Quant data shows HIND's Liabilities and Shareholders Equity at $10.2 million in Q1 2026, $6.5 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | 9.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.18 Mn |
| Mar 31, 2026 | 10.19 Mn |
| Dec 31, 2025 | 6.50 Mn |
| Sep 30, 2025 | 7.05 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 6.39 Mn |
| Mar 31, 2024 | 8.23 Mn |
| Dec 31, 2023 | 10.66 Mn |
| Sep 30, 2023 | 7.83 Mn |
| Jun 30, 2023 | 11.85 Mn |
| Mar 31, 2023 | 16.35 Mn |
| Dec 31, 2022 | 11.14 Mn |
| Sep 30, 2022 | 26.49 Mn |
| Jun 30, 2022 | 40.36 Mn |
| Mar 31, 2022 | 45.62 Mn |
| Dec 31, 2021 | 52.53 Mn |
| Sep 30, 2021 | 90.79 Mn |